Novartis plans to establish a new 46,000-square-foot radioligand therapy (RLT) manufacturing site in Denton, Texas. This purpose-built RLT site will be the company’s fifth in the US and first manufacturing facility in Texas, and marks further progress in the company’s $23 billion US investment.
The Denton site is expected to create new Novartis jobs in bioengineering, advanced manufacturing, quality and operations, supporting economic growth in Denton and surrounding communities. Construction is scheduled to begin this year, with the site expected to become fully operational in 2028. Denton officials have said the cost of the plant will be $280 million.
The Texas site will join a comprehensive Novartis RLT manufacturing network, with existing US sites in New Jersey, Indiana and California and a recently announced site to be constructed in Florida — providing unmatched RLT capacity from coast to coast. Each dose of RLT is custom-made and time-sensitive, making proximity to patients and treatment centers critical. By harnessing the power of targeted radiation and applying it to advanced cancers, RLT is designed to deliver treatment directly to target cells anywhere in the body…